Exenatide Completed Phase 4 Trials for Type 2 Diabetes Mellitus / Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT02303730Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes
NCT01006889Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease